Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Trevor Jamison, Elias Jabbour, Nitin Jain, Omer Karrar, Fadi Haddad, Partow Kebriaei, Issa Khouri, Uday Popat, Hui Yang, Jayastu Senapati, Eitan Kugler, Rebecca Garris, Guillermo Garcia-Manero, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2025-1558

Published: 2025

Journal Articles

A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes

Manuel Maroun, Hagop Kantarjian, Nitin Jain, Omer Karrar, Fadi Haddad, Guilin Tang, Sanam Loghavi, Keyur Patel, Walid Macaron, Partow Kebriaei, Issa Khouri, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Nicholas Short

Blood (2025) 146 (Supplement 1): 551.

https://doi.org/10.1182/blood-2025-551

Published: 2025

Journal Articles

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Nitin Jain, Fadi Haddad, Partow Kebriaei, Issa Khouri, Elizabeth Shpall, Richard Champlin, Jayastu Senapati, Eitan Kugler, Omer Karrar, Elias Maroun, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 549.

https://doi.org/10.1182/blood-2025-549

Published: 2025

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Blood (2025) 146 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2025-5951

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Issa Khouri, Susan Wu, Fadi Haddad, Denai Milton, Tapan Kadia, Nicholas Short, Koji Sasaki, Jin Im, David Marin, Rohtesh Mehta, Gabriela Rondon, Hind Rafei, Jeremy Ramdial, Guillermo Garcia-Manero, Dan Li, Alison Gulbis, Bouthaina Dabaja, Elias Jabbour, Qing Ma

Blood (2025) 146 (Supplement 1): 6022.

https://doi.org/10.1182/blood-2025-6022

Published: 2025

Journal Articles

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood (2022) 139 (12): 1908–1919.

https://doi.org/10.1182/blood.2021013290

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R. Popat, Qaiser Bashir, Chitra M. Hosing, Yago Nieto, Amin M. Alousi, Muzaffar H. Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E. Champlin, Partow Kebriaei

Blood (2020) 136 (15): 1786–1789.

https://doi.org/10.1182/blood.2019004685

Published: 2020

Includes: Supplemental data

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Constantine S. Tam, Susan O’Brien, William Plunkett, William Wierda, Alessandra Ferrajoli, Xuemei Wang, Kim-Anh Do, Jorge Cortes, Issa Khouri, Hagop Kantarjian, Susan Lerner, Michael J. Keating

Blood (2014) 124 (20): 3059–3064.

https://doi.org/10.1182/blood-2014-06-583765

Published: 2014

Includes: Supplemental data

Journal Articles

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

Sai Ravi Pingali, MD, Milton Denai, M S, Antonio Di Stasi, MD, Partow Kebriaei, MD, Uday R Popat, MD, Amin Alousi, MD, Paolo Anderlini, MD, Simrit Parmar, MD, Chitra M. Hosing, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Sairah Ahmed, MD, Betul Oran, MD, Elizabeth J Shpall, MD, Issa Khouri, MD, Marina Konopleva, MD, PhD, Gheath Alatrash, D.O., Ph.D., Richard E Champlin, MD, Stefan O. Ciurea, MD

Blood (2013) 122 (21): 4523.

https://doi.org/10.1182/blood.V122.21.4523.4523

Published: 2013

Journal Articles

The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT)

Armin Ghobadi, MD, Amir Hamdi, MD, Piyanuch Kongtim, MD, Denai Milton, Amin Alousi, MD, Paolo Anderlini, MD, Stefan O. Ciurea, MD, Betul Oran, MD, Issa Khouri, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Partow Kebriaei, MD, Uday R Popat, MD, Katy Rezvani, MD, PhD, Roy F Chemaly, MD, MPH, Elizabeth J Shpall, MD, Richard E Champlin, MD, Qaiser Bashir, MD

Blood (2013) 122 (21): 4531.

https://doi.org/10.1182/blood.V122.21.4531.4531

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Sai Ravi Pingali, MD, Rima M Saliba, PhD, Veronica R. Smith, APN, Farzaneh Maadani, Kehinde U.A. Adekola, MBBS, Uday R Popat, MD, Muzaffar H. Qazilbash, MD, Qaiser Bashir, MD, Issa Khouri, MD, Partow Kebriaei, MD, Stefan O. Ciurea, MD, Paolo Anderlini, MD, Nina Shah, MD, Yago Nieto, MD, PhD, Richard E Champlin, MD, Chitra M. Hosing, MD

Blood (2013) 122 (21): 4515.

https://doi.org/10.1182/blood.V122.21.4515.4515

Published: 2013

Journal Articles

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Blood (2013) 122 (21): 2167.

https://doi.org/10.1182/blood.V122.21.2167.2167

Published: 2013

Journal Articles

Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia

Fleur M. Aung, MD, Benjamin Lichtiger, MD PhD, Amin Alousi, MD, Sairah Ahmed, MD, Paolo Anderlini, MD, Borje S. Andersson, MD, PhD, Qaiser Bashir, MD, Stefan O. Ciurea, MD, Roy B Jones, PhD MD, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Betul Oran, MD, Simrit Parmar, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Issa Khouri, MD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Uday R Popat, MD

Blood (2013) 122 (21): 5449.

https://doi.org/10.1182/blood.V122.21.5449.5449

Published: 2013

Journal Articles

Double Hit Lymphoma: M.D. Anderson Experience

Yasuhiro Oki, MD, Mansoor Noorani, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Alma Rodriguez, M.D., Fredrick B Hagemeister, MD, Nathan Fowler, MD, Michael Wang, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Bouthaina S. Dabaja, MD, Chelsea Pinnix, M.D., Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Issa Khouri, MD, Jason R. Westin, MD, Luis E Fayad

Blood (2013) 122 (21): 1776.

https://doi.org/10.1182/blood.V122.21.1776.1776

Published: 2013

Journal Articles

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Betul Oran, MD, MS, Farhad Ravandi, MD, Hady Ghanem, MD, Issa Khouri, MD, Guillermo Garcia-Manero, MD, Michael S Mathisen, PharmD, Qaiser Bashir, MD, Rima M Saliba, PhD, Maria Khouri, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 2029.

https://doi.org/10.1182/blood.V120.21.2029.2029

Published: 2012

Journal Articles

Comorbidity and Outcomes for Patients Over Age 65 Years Treated with Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Henry J. Conter, MD, MSc, Nhu-Nhu Nguyen, Gabriela Rondon, MD, Julianne Chen, Elizabeth J Shpall, MD, Issa Khouri, MD, Sergio A Giralt, MD, Richard E. Champlin, Marcos DeLima, MD

Blood (2012) 120 (21): 2032.

https://doi.org/10.1182/blood.V120.21.2032.2032

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Optimizing essential, complex hematologic care for patients living with disabilities

Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT)

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning

Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia

Double Hit Lymphoma: M.D. Anderson Experience

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Comorbidity and Outcomes for Patients Over Age 65 Years Treated with Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only